Healthcare -
Biotechnology - NASDAQ - US
$ 1.72
0.585 %
$ 15.9 M
Market Cap
-0.27
P/E
1. INTRINSIC VALUE
Balance Sheet
SAB Biotherapeutics, Inc.
| Current Assets | 58.9 M |
| Cash & Short-Term Investments | 56.6 M |
| Receivables | 0 |
| Other Current Assets | 2.34 M |
| Non-Current Assets | 25 M |
| Long-Term Investments | 0 |
| PP&E | 24.7 M |
| Other Non-Current Assets | 350 K |
| Current Liabilities | 10.8 M |
| Accounts Payable | 946 K |
| Short-Term Debt | 1.85 M |
| Other Current Liabilities | 8.01 M |
| Non-Current Liabilities | 15.8 M |
| Long-Term Debt | 4.05 M |
| Other Non-Current Liabilities | 11.8 M |
EFFICIENCY
Earnings Waterfall
SAB Biotherapeutics, Inc.
| Revenue | 2.24 M |
| Cost Of Revenue | 3.75 M |
| Gross Profit | -1.51 M |
| Operating Expenses | 36.6 M |
| Operating Income | -38.1 M |
| Other Expenses | 4.12 M |
| Net Income | -42.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
SAB Biotherapeutics, Inc.
| Net Income | -42.2 M |
| Depreciation & Amortization | 3.75 M |
| Capital Expenditures | -197 K |
| Stock-Based Compensation | 2.42 M |
| Change in Working Capital | 2.33 M |
| Others | 8.05 M |
| Free Cash Flow | -25.3 M |
Wall Street Analysts Price Targets
SAB Biotherapeutics, Inc.
Wall Street analysts predict an average 1-year price target for SABS of $6.2 , with forecasts ranging from
a
low of
$3 to a high of $8 .
SABS Lowest Price Target
Wall Street Target
3 USD
74.42%
SABS Average Price Target
Wall Street Target
6.2 USD
260.47%
SABS Highest Price Target
Wall Street Target
8 USD
365.12%
4. DIVIDEND
ANALYSIS
SABS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
SAB Biotherapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Dec 07, 2023
|
Bought
1.53 K USD
|
Sullivan Eddie Joe
Chief Executive Officer
|
+ 1740
|
0.88 USD |
|
1 year ago
Nov 30, 2023
|
Bought
4.5 K USD
|
King Michael
CHIEF FINANCIAL OFFICER
|
+ 5000
|
0.9 USD |
|
1 year ago
Nov 29, 2023
|
Bought
9.84 K USD
|
Reich Samuel J
Executive Chairman
|
+ 11000
|
0.8947 USD |
|
2 years ago
Sep 13, 2022
|
Bought
7.3 K USD
|
HAMILTON CHRISTINE E
director, 10 percent owner:
|
+ 10000
|
0.7297 USD |
|
2 years ago
Sep 07, 2022
|
Bought
10.3 K USD
|
Sullivan Eddie Joe
CHIEF EXECUTIVE OFFICER
|
+ 14000
|
0.7368 USD |
|
3 years ago
Oct 26, 2021
|
Sell 2.2 K
USD
|
Beyer Russell P
Chief Financial Officer
|
- 278
|
7.9 USD |
|
3 years ago
Oct 13, 2021
|
Bought
5.05 K USD
|
Katz Ilan
director, 10 percent owner:
|
+ 500
|
10.105 USD |
|
3 years ago
Oct 14, 2021
|
Bought
10.1 K USD
|
Reich Samuel J
CEO and CFO
|
+ 1000
|
10.11 USD |
|
3 years ago
Oct 01, 2021
|
Bought
131 K USD
|
Spragens Jeffrey G
Director
|
+ 13000
|
10.07 USD |
|
3 years ago
Oct 01, 2021
|
Bought
10.1 K USD
|
Katz Ilan
director, 10 percent owner:
|
+ 1000
|
10.09 USD |
|
4 years ago
Jan 14, 2021
|
Bought
4.17 M USD
|
Reich Samuel J
CEO and CFO
|
+ 417200
|
10 USD |
|
4 years ago
Jan 14, 2021
|
Bought
4.17 M USD
|
Katz Ilan
director, 10 percent owner:
|
+ 417200
|
10 USD |
|
4 years ago
Jan 14, 2021
|
Bought
4.17 M USD
|
Big Cypress Holdings LLC
CEO and CFO
|
+ 417200
|
10 USD |
7. News
SAB BIO to Participate in Upcoming Investor Conferences
MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human anti-thymocyte immunoglobulin (hIgG) that potentially delays the onset or progression of type 1 diabetes (T1D), today announced that members of its management team will participate in the following investor conferences:
globenewswire.com
- 1 month ago
Why Is SAB BIO Stock Trading Lower On Tuesday?
On Tuesday, SAB BIO SABS released topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers.
benzinga.com
- 1 month ago
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support that SAB-142 is well-positioned for re-dosing in outpatient setting for type 1 diabetes Results will be presented in an R&D webinar event today at 8:00 am ET; registration details below MIAMI, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced positive topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers. The study met its primary objectives related to safety and pharmacodynamic activity enabling SAB-142 to advance to Phase 2b clinical development.
globenewswire.com
- 1 month ago
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO's management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division chief of the Pediatric Endocrinology Division at the University of Florida and Silverstein Family Eminent Scholar Chair in Pediatric Endocrinology.
globenewswire.com
- 1 month ago
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year.
globenewswire.com
- 3 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into SAB Biotherapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / October 3, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
accesswire.com
- 4 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / September 30, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
accesswire.com
- 5 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeutics
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
accesswire.com
- 5 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherapeutics
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
accesswire.com
- 5 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
accesswire.com
- 5 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into SAB Biotherapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
accesswire.com
- 5 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own SAB Biotherapeutics, Inc. ("SABS" or the "Company") (NASDAQ:SABS) stock purchased prior to October 17, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Big Cypress Acquisition Corp. (BCYP), and whether the Board of SABS harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
accesswire.com
- 5 months ago
8. Profile
Summary
SAB Biotherapeutics, Inc. SABS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 15.9 M
Dividend Yield
0.00%
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Contact
2100 East 54th Street North, Sioux Falls, SD, 57104
https://www.sabbiotherapeutics.com
IPO
Date
Feb. 9, 2021
Employees
57
Officers
Dr. Christoph Bausch M.B.A., Ph.D.
Executive Vice President & Chief Operating Officer
Dr. Edward D. Hamilton D.V.M.
Co-Founder & Board Observer
Ms. Christine E. Hamilton M.B.A.
Co-Founder & Independent Director
Mr. Samuel J. Reich
Chief Executive Officer & Executive Chairman
Dr. Eddie Joe Sullivan Ph.D.
Co-Founder, President & Director
Dr. Alexandra Kropotova M.B.A., M.D.
Executive Vice President & Chief Medical Officer
Dr. Carlos N. Carillo Ph.D.
Senior Vice President of Regulatory Affairs